Kura posts Krazati combo data on drug designed to unleash KRAS inhibitors’ potential
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to...
Kura Oncology has published early data on darlifarnib in combination with Bristol Myers Squibb’s Krazati, linking the drug candidate to response rates of up to 69% when given with the KRAS inhibitor.